Immunotherapy efficacy as monotherapy is negligible for glioblastoma (GBM). We
hypothesized that combining therapeutic vaccination using a plasmid encoding an epitope …

Purpose The prognosis for glioma patients is poor, and development of new treatments is
critical. Previously, we engineered polymer-based vaccines that control GM-CSF, CpG …

Combination immunotherapy has emerged as a promising strategy to increase the immune
response in glioblastoma (GBM) and overcome the complex immunosuppression occurring …

The promise of dendritic cell (DC)–based immunotherapy has been established by two
decades of translational research. Of the four malignancies most targeted with clinical DC …

We examined a “double-punch” approach to overcome the escape of glioblastoma cells to
the immune surveillance: increasing the immune systems activation by an active specific …

Owing to the limited therapeutic efficacy of glioma vaccines, new strategies are required to
improve cancer vaccines. Our study aimed to assess the therapeutic efficacy of a glioma …

Survival of glioma (GBM) patients treated with the current standard of care remains dismal.
Immunotherapeutic approaches that harness the cytotoxic and memory potential of the host …

Despite strides in immunotherapy, glioblastoma multiforme (GBM) remains challenging due
to low inherent immunogenicity and suppressive tumor microenvironment. Converting “cold” …

The exploration of multifunctional nanomedicine has prompted interest in improving
glioblastoma (GBM) prognosis. In this study, we constructed tumor microenvironment (TME) …

Cancer stem cells are initiating cells of cancer and propagate its growth through self-
renewal and differentiation of its daughter cells. CD133 is a cell surface antigen that is …